Develops gene-silencing therapies based on its proprietary DNA-directed RNA interference technology for genetic diseases.
Benitec Biopharma Inc., headquartered in Hayward, California, is an innovative biotechnology company in the developmental stages, dedicated to advancing novel genetic medicines. Specializing in DNA-directed RNA interference (RNAi) therapies, Benitec Biopharma focuses on addressing chronic and life-threatening human conditions through groundbreaking approaches. One of its key initiatives includes the development of BB-301, a promising gene therapy agent based on adeno-associated virus technology, aimed at treating oculopharyngeal muscular dystrophy.
Founded in 1995, Benitec Biopharma has established itself as a leader in RNAi therapeutics, leveraging its expertise to pioneer transformative treatments. The company's commitment to genetic medicine underscores its mission to innovate and deliver impactful solutions that improve patient outcomes globally. With a strong foundation in research and development, Benitec Biopharma continues to push the boundaries of biotechnology, striving to make significant advancements in the field of genetic-based therapies.